PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.37%
Negative revenue growth while META stands at 12.29%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-2.95%
Negative gross profit growth while META is at 12.33%. Joel Greenblatt would examine cost competitiveness or demand decline.
1.28%
EBIT growth below 50% of META's 10.27%. Michael Burry would suspect deeper competitive or cost structure issues.
1.28%
Operating income growth under 50% of META's 16.44%. Michael Burry would be concerned about deeper cost or sales issues.
272.08%
Net income growth above 1.5x META's 10.17%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
80.62%
EPS growth above 1.5x META's 10.47%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
82.72%
Diluted EPS growth above 1.5x META's 11.04%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.41%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-0.09%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
5.99%
Similar OCF growth to META's 6.39%. Walter Schloss would assume comparable operations or industry factors.
13.24%
Positive FCF growth while META is negative. John Neff would see a strong competitive edge in net cash generation.
9074.31%
10Y revenue/share CAGR above 1.5x META's 1223.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
821.87%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
127.35%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
1079.29%
5Y OCF/share CAGR above 1.5x META's 653.02%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
153.67%
3Y OCF/share CAGR 1.25-1.5x META's 125.05%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
12341.30%
Net income/share CAGR above 1.5x META's 2770.56% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
2325.52%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
123.46%
3Y net income/share CAGR 50-75% of META's 194.47%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
4286.41%
5Y equity/share CAGR above 1.5x META's 101.78%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
171.02%
3Y equity/share CAGR above 1.5x META's 66.56%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.75%
Firm’s AR is declining while META shows 14.10%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
52.01%
Inventory growth of 52.01% while META is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
5.49%
Similar asset growth to META's 5.19%. Walter Schloss finds parallel expansions or investment rates.
5.27%
Similar to META's 5.80%. Walter Schloss finds parallel capital usage or profit distribution strategies.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Our R&D shrinks while META invests at 6.52%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-3.83%
We cut SG&A while META invests at 12.01%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.